Email this page
Print
Bookmark and share
Bigger
Smaller
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Quick Links
Articles on vildagliptin from NPS RADARArticles on vildagliptin from NPS RADAR
| Title | Content Type | Date | Description |
|---|---|---|---|
| Sitagliptin, vildagliptin and saxagliptin — dipeptidyl peptidase-4 inhibitors (‘gliptins’) for add-on therapy in type 2 diabetes mellitus | Professional publication - NPS RADAR - Review | 2011-07-01 00:00:00 | DPP-4 inhibitors (‘gliptins’) are a recently introduced class of oral drugs for improving glycaemic control in patients with type 2 diabetes mellitus. They are approved as add-on therapy in combination with either metformin or a sulfonylurea in patients poorly controlled with metformin, a sulfonylurea or a thiazolidinedione. The RADAR article on gliptins has been updated to reflect the listing of another gliptin. Saxagliptin was added to the PBS on 1 June 2011. |
| Vildagliptin with metformin (Galvumet) fixed-dose combination tablets PBS listed for type 2 diabetes | Professional publication - NPS RADAR - Brief item | 2011-04-01 00:00:00 | Vildagliptin with metformin tablets (Galvumet) in fixed-dose combinations of 50/500 mg, 50/850 mg and 50/1000 mg are available on the PBS for the treatment of type 2 diabetes. |
View all RADAR articles by date, by therapeutic topic, or by active ingredient, or find out more about NPS RADAR.
NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.
Date published: 2010-08-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
